Amanta Healthcare India IPO is scheduled to be listed on September 9, 2025. According to grey market trends, the shares are trading at a small premium. The listing at BSE and NSE is eagerly awaited by investors.
Amanta Healthcare IPO Listing Date in Focus
The pharmaceutical sector of India is one the biggest sources of investor interest. As Amanta Healthcare‘s IPO is ready to take off on September 9, 2025, the firm has seen her shares being subscribed to with colorful scoops from its retail and institutional investors. The general perception that prevails is that the company is on a strong and bright path.
On BSE and NSE, the IPO listing will be simultaneous thus, witnessing another milestone for the company and co-owners. Wall Street speculators are currently discerning the grey market trend that indicates a small premium which, thusly, guarantees a measured positive reaction to the arrival of the shares.
Strong IPO Subscription Highlights
The subscription for Amanta Healthcare’s IPO was made public from September 1 to 3, 2025, with the allotment being confirmed on September 4. The price split for the IPO was pegged at ₹120-₹126 per share, thereby enabling the company to collect ₹126 crore by issuing 1 crore equity shares subsidiary fresh.
On the stock exchange, the IPO was 82.61 times oversubscribed in total as per BSE data. Retail investors were responsible for a 54.98 times subscription of the total while non-institutional investors (NIIs) were very active and drove the subscription to the maximum at 209.42 times. Qualified institutional buyers (QIBs) were good partners in the project as they committed 35.86 times.
Beeline Capital Advisors Pvt. Ltd. was the book-running lead manager, MUFG Intime India Pvt. Ltd. acted as the IPO registrar.
Also Read: SEBI IPO Approvals: 13 Companies Including Urban Co
Grey Market Premium Signals
The grey market premium (GMP) of Amanta Healthcare IPO shares before the listing indicates a subdued trend. At present, the GMP is ₹9 per share, implying a tentative listing price of ₹135, which is 7.14% higher than the issue price.
Market watchers say that this moderate GMP is good for a balanced sentiment. On the one hand, the need is still quite healthy, on the other hand, the investors seem to be very cautious in line with the current market situation and sector-specific issues in India’s pharmaceutical industry.
Market Implications and Investor Insight
The listing of the Amanta Healthcare IPO has taken the big spotlight in front of retail and institutional investors downstairs in India. In essence, a relatively low GMP suggests a stock market that is likely to open only slightly above the issue price and at the same time very limited gains within a short period will be possible.
The financial world notes that the IPO success will largely be decided by the demand for the shares after the stock market listing and the overall market sentiment. The pharmaceutical sector in India which has been the primary source of domestic healthcare needs has escalated the exports of India to other countries as well, thus creating excellent opportunities for long-term growth which consequently supports optimism.
The listing is believed to have a positive effect on the stock market as the liquidity of shareholding will expand and more stakeholders will be able to actively engage in the firm’s progression.
Potential Growth Drivers
The company Amanta is aligned with a solid strategy in the Indian pharmaceutical market and has its attention fixed on those segments of the medicine that are most required by the market. The company’s approach to doing business and its market coverage, therefore, are predicted to become the keys to increasing profits over the next few years.
Key factors likely to influence the IPO’s performance include:
- Market expansion of pharmaceutical products in India and worldwide.
- Investor demand has been strong, as reflected in high subscription numbers.
- The grey market’s current sentiment is somewhat positive, as also can be seen from the prices.
- Government laws and regulation support related to the domestic pharmaceutical sector.
- Operational expansion and strategic product portfolio development.
FAQ’s
When is Amanta Healthcare going to be listed?
The Amanta Healthcare will be listed on both BSE and NSE on September 9, 2025.
What will be the listing price of Amanta Healthcare?
Considering the grey market premium, the provisional listing price is likely to be a bit higher than the issue price, showing that investors are moderately positive.
What was the Amanta Healthcare IPO price band?
The IPO was priced at ₹120–₹126 per share, raising ₹126 crore through the issue of 1 crore equity shares.
How was the Amanta Healthcare IPO subscription response?
The IPO was 82.61 times oversubscribed. NIIs subscribed 209.42x, QIBs 35.86x, and retail investors 54.98x.
What is the grey market premium (GMP) of Amanta Healthcare IPO?
The GMP is around ₹9 per share, implying a tentative listing price of ₹135, about 7.14% above the issue price.
Who managed the Amanta Healthcare IPO?
Beeline Capital Advisors Pvt. Ltd. acted as the book-running lead manager, while MUFG Intime India Pvt. Ltd. was the IPO registrar.
READ MORE ON